Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
430.6 INR | -1.86% | -4.36% | +0.10% |
25/04 | Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024 | |
25/04 | Laurus Labs' Consolidated Profit Falls in Fiscal Q4 | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 123.34 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.10% | 2.84B | C | ||
+31.52% | 690B | C+ | ||
+24.18% | 546B | B | ||
-5.21% | 358B | C+ | ||
+17.02% | 323B | B- | ||
+5.01% | 287B | C+ | ||
+14.02% | 235B | B+ | ||
+5.00% | 199B | B- | ||
-10.22% | 195B | A+ | ||
+3.98% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAURUSLABS Stock
- LAURUSLABS Stock
- Ratings Laurus Labs Limited